Oncolytics Biotech, Inc. ONCY
ONCY emerged from our extended watchlist and stole the show yesterday with an exceptional intraday run. The stock saw an early morning low of .80 then proceeded to bull its way upward for the remainder of the session, breaking through the 200DMA (.92) and setting its daily high of 1.10 inside of the last hour of trading.
The spike was good for gains of up to 37% on the day, and ONCY held a vast majority of those gains, closing at 1.07. We were extremely pleased with our timing in flagging this play when we did; the strong performance came on more than 12x the 3-month average number of shares traded, setting a new 52-week high for volume in the process.
With the kind of breakout momentum we saw build up in ONCY yesterday, we’re going to continue to reserve a spot for it on our watchlist, provided the stock can maintain support at or above the .85-.87 area on any pullbacks. It’s gapping up in the premarket this morning, so there’s a reasonable chance of some early profit-taking today.
Ohr Pharmaceutical, Inc. OHRP
We also wanted to make a note of another of our stated items of interest which made a nice move right off the bat yesterday. OHRP came off of our extended watchlist to trade in a range from 8.55-10.58, a 24% intraday increase.
Volume came in at more 16x the 3-month average for the session. The stock held more than half of its daily advances into the close (9.78), and is gapping up slightly in premarket trading this morning. The stock will receive our continued attention in the event that it can hold support above 9.50.
Biocept, Inc. BIOC
BIOC began appearing in our reports for the first time back on February 17th via our extended watchlist. Subsequent to that point, we witnessed the stock spike in a big way from a low of 1.35 up to a high of 4.91 just seven sessions later on February 25th; an initial run equal to an increase of 264%
After consolidating off of that high the stock found support at 2.73 on Friday before beginning to rebound. Yesterday brought a continuation of that recovery as BIOC found its way back to 3.94, which marks a 44% swing.
MDR, FNJN, AMCO